Mengis Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Mengis Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10,450	Closed	-$156K	–	221
2026 Q2	$156K	Buy	+10,450	New	+$145K	0.02%	217

Other funds holding CRVS

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AIM

Avity Investment Management Greenwich, Connecticut $1.6B AUM 32.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Mengis Capital Management's CRVS Position: Q3 2026 in Review

Mengis Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2026, closing a stake of 10,450 shares — an estimated $156K sold.

Mengis Capital Management first reported a position in CRVS in Q2 2026 and held it in 1 quarter. The position peaked at $156K in Q2 2026. 6 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

Mengis Capital Management reported no remaining Corvus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Mengis Capital Management sold 10,450 Corvus Pharmaceuticals shares in Q3 2026, an estimated $156K.
Mengis Capital Management first reported a position in Corvus Pharmaceuticals in Q2 2026 and held it in 1 quarter.
Mengis Capital Management's Corvus Pharmaceuticals position peaked at $156K in Q2 2026.
6 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Mengis Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.